Compare AGI & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGI | RGEN |
|---|---|---|
| Founded | 2003 | 1981 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8B | 8.2B |
| IPO Year | 1999 | N/A |
| Metric | AGI | RGEN |
|---|---|---|
| Price | $37.80 | $159.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | $41.00 | ★ $174.90 |
| AVG Volume (30 Days) | ★ 2.3M | 680.3K |
| Earning Date | 10-29-2025 | 10-28-2025 |
| Dividend Yield | ★ 0.27% | N/A |
| EPS Growth | ★ 112.89 | N/A |
| EPS | ★ 1.28 | 0.03 |
| Revenue | ★ $1,609,300,000.00 | $707,890,000.00 |
| Revenue This Year | $40.10 | $17.84 |
| Revenue Next Year | $33.02 | $12.57 |
| P/E Ratio | ★ $29.44 | $6,166.78 |
| Revenue Growth | ★ 31.30 | 11.74 |
| 52 Week Low | $17.80 | $102.97 |
| 52 Week High | $39.44 | $182.52 |
| Indicator | AGI | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 62.40 | 49.95 |
| Support Level | $36.86 | $156.01 |
| Resistance Level | $39.44 | $165.02 |
| Average True Range (ATR) | 1.31 | 4.69 |
| MACD | 0.04 | -1.34 |
| Stochastic Oscillator | 61.44 | 21.10 |
Alamos Gold Inc acquires, explores, and produces gold and other precious metals, and operates in two principal geographic areas: Canada and Mexico. The company has four operating segments being Young-Davidson, Island Gold and Magino mines operate in Canada, and the Mulatos mine operates in Sonora, Mexico. The company generates maximum revenue from the Mulatos mines.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.